
    
      This is an open-label, Phase I/II study of intravitreally administered 0.3mg ranibizumab
      (Lucentis) in subjects with DME (diabetic macular edema) previously treated with intravitreal
      bevacizumab (Avastin) with a randomized comparative dosing strategy, monthly vs
      "treat-and-extend." Thirty patients total will be enrolled in the study, 15 in each group.
      This study will have a 1-year treatment period. The recruitment period will occur over 1 year
      with total potential study duration of 2 years.
    
  